PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

NCT06533384 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

310

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
DRUG: 9 cycles of Camrelizumab as adjuvant therapy.

Sponsor

Guangdong Provincial People's Hospital